Scheduled Maintenance

We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.

LA JOLLA PHARMACEUTICAL CO (LJPC)

US5034596040 - Common Stock

6.22  0 (0%)

Fundamental Rating

2

Taking everything into account, LJPC scores 2 out of 10 in our fundamental rating. LJPC was compared to 588 industry peers in the Biotechnology industry. While LJPC seems to be doing ok healthwise, there are quite some concerns on its profitability. LJPC is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LJPC has reported negative net income.
LJPC had negative earnings in 4 of the past 5 years.
LJPC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Industry RankSector Rank
ROA 3.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -5.53%
PM (TTM) 8.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

LJPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LJPC has less shares outstanding
Compared to 1 year ago, LJPC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -12.76, we must say that LJPC is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for LJPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.76
ROIC/WACCN/A
WACC9.48%

2.3 Liquidity

LJPC has a Current Ratio of 4.02. This indicates that LJPC is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.52 indicates that LJPC has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 3.52

More info and screens

4

3. Growth

3.1 Past

LJPC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
The Revenue for LJPC has decreased by -33.79% in the past year. This is quite bad
LJPC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 161.44% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-27.27%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Revenue growth Q2Q-34.35%

3.2 Future

The Earnings Per Share is expected to grow by 38.81% on average over the next years. This is a very strong growth
Based on estimates for the next years, LJPC will show a small growth in Revenue. The Revenue will grow by 6.65% on average per year.
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LJPC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 26.51, the valuation of LJPC can be described as expensive.
The average S&P500 Price/Forward Earnings ratio is at 20.88. LJPC is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 26.51

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -120.41

4.3 Compensation for Growth

A cheap valuation may be justified as LJPC's earnings are expected to decrease with -5.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%

More info and screens

0

5. Dividend

5.1 Amount

LJPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LA JOLLA PHARMACEUTICAL CO

NASDAQ:LJPC (8/19/2022, 7:00:02 PM)

6.22

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap158.96M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.51
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.99%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -5.53%
PM (TTM) 8.54%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.02
Quick Ratio 3.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-92.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y